Teachers Retirement System of The State of Kentucky Buys 19,000 Shares of PTC Therapeutics, Inc. $PTCT

Key Points

• Teachers Retirement System of Kentucky boosted its stake in PTC Therapeutics by 86.9%, adding 19,000 shares to hold 40,858 shares valued at about $3.10 million (≈0.05% of the company).
• PTC reported a weak quarter with EPS of ($1.67) versus consensus ($0.21) and revenue of $164.7M versus $281.5M expected, a 22.7% year‑over‑year revenue decline.
• Company insiders have sold 126,492 shares (~$8.63M) in the past three months, while analysts are mixed — the consensus rating is "Moderate Buy" with an average price target of $84.40 amid several recent downgrades and target cuts.

Teachers Retirement System of The State of Kentucky grew its stake in shares of PTC Therapeutics, Inc. (NASDAQ:PTCT - Free Report) by 86.9% in the fourth quarter, according to its most recent filing with the Securities & Exchange Commission. The firm owned 40,858 shares of the biopharmaceutical company's stock after acquiring an additional 19,000 shares during the period. Teachers Retirement System of The State of Kentucky owned about 0.05% of PTC Therapeutics worth $3,103,000 at the end of the most recent reporting period.

Other large investors also recently modified their holdings of the company. Vanguard Group Inc. raised its holdings in shares of PTC Therapeutics by 6.2% in the 4th quarter. Vanguard Group Inc. now owns 8,803,203 shares of the biopharmaceutical company's stock worth $668,691,000 after purchasing an additional 514,204 shares during the period. M&T Bank Corp purchased a new position in PTC Therapeutics in the fourth quarter valued at approximately $1,859,000. Universal Beteiligungs und Servicegesellschaft mbH grew its holdings in PTC Therapeutics by 14.6% during the fourth quarter. Universal Beteiligungs und Servicegesellschaft mbH now owns 151,401 shares of the biopharmaceutical company's stock valued at $11,502,000 after purchasing an additional 19,300 shares during the period. Salomon & Ludwin LLC purchased a new stake in PTC Therapeutics in the fourth quarter worth $41,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its position in PTC Therapeutics by 9.1% in the fourth quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 22,832 shares of the biopharmaceutical company's stock worth $1,734,000 after buying an additional 1,901 shares during the last quarter.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on PTCT. Wall Street Zen cut PTC Therapeutics from a "buy" rating to a "hold" rating in a research report on Saturday, February 21st. Bank of America lowered their price objective on PTC Therapeutics from $97.00 to $93.00 and set a "buy" rating on the stock in a research note on Friday, February 20th. Raymond James Financial began coverage on shares of PTC Therapeutics in a report on Friday, April 10th. They set an "outperform" rating and a $108.00 price objective on the stock. TD Cowen reiterated a "hold" rating on shares of PTC Therapeutics in a research report on Thursday, January 29th. Finally, Jefferies Financial Group downgraded shares of PTC Therapeutics from a "buy" rating to a "hold" rating and reduced their target price for the stock from $91.00 to $76.00 in a research note on Monday, March 30th. One analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, five have assigned a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock has an average rating of "Moderate Buy" and an average price target of $84.40.

Insiders Place Their Bets

In other PTC Therapeutics news, Director Stephanie Okey sold 15,167 shares of the firm's stock in a transaction dated Tuesday, March 10th. The stock was sold at an average price of $70.00, for a total value of $1,061,690.00. Following the sale, the director owned 8,000 shares of the company's stock, valued at $560,000. This trade represents a 65.47% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Also, EVP Lee Scott Golden sold 10,000 shares of PTC Therapeutics stock in a transaction dated Thursday, March 5th. The shares were sold at an average price of $63.38, for a total value of $633,800.00. Following the sale, the executive vice president owned 79,944 shares of the company's stock, valued at approximately $5,066,850.72. This trade represents a 11.12% decrease in their position. The SEC filing for this sale provides additional information. Over the last three months, insiders sold 126,492 shares of company stock worth $8,634,621. 5.50% of the stock is owned by corporate insiders.

PTC Therapeutics Price Performance

Shares of NASDAQ:PTCT opened at $69.22 on Tuesday. The firm has a fifty day moving average price of $68.13 and a two-hundred day moving average price of $72.10. The company has a market cap of $5.74 billion, a price-to-earnings ratio of 8.94 and a beta of 0.55. PTC Therapeutics, Inc. has a one year low of $35.95 and a one year high of $87.50.

PTC Therapeutics (NASDAQ:PTCT - Get Free Report) last issued its quarterly earnings data on Thursday, February 19th. The biopharmaceutical company reported ($1.67) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.21) by ($1.46). The business had revenue of $164.68 million during the quarter, compared to analysts' expectations of $281.45 million. PTC Therapeutics had a negative return on equity of 362.45% and a net margin of 39.44%.The company's quarterly revenue was down 22.7% on a year-over-year basis. During the same quarter last year, the business posted ($0.85) EPS. Equities research analysts expect that PTC Therapeutics, Inc. will post -0.76 EPS for the current fiscal year.

PTC Therapeutics Profile

PTC Therapeutics, Inc is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule and biologic therapies for the treatment of rare genetic disorders. Since its founding in 1998, PTC has dedicated its efforts to addressing high unmet medical needs by targeting underlying genetic causes of disease. The company's research platform emphasizes mechanisms such as nonsense suppression and RNA modulation, enabling the development of novel treatments for conditions with limited therapeutic options.

Among PTC's approved products is Translarna (ataluren), a first-in-class therapy designed to treat nonsense mutation Duchenne muscular dystrophy in select markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.